Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty.

Masaya ShinoharaRyou WadaShintaro YaoKensuke YanoKatsuya AkitsuHideki KoikeToshio KinoshitaHitomi YuzawaTakeya SuzukiTadashi FujinoTakanori Ikeda

Published in: Journal of arrhythmia (2019)

OACs are substantially safe and effective for preventing thromboembolic events in nonsevere frail patients over 80 years of age. Particularly, DOACs can be used more safely than warfarin.

Keyphrases

atrial fibrillation
oral anticoagulants
end stage renal disease
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
heart failure
coronary artery disease
catheter ablation
left ventricular